Bd receives fda 510(k) clearance for potentially transformative fingertip blood collection device

Bd minidraw™ capillary blood collection system enables lab-quality blood testing from less invasive method than venous collection in more convenient locations franklin lakes, n.j. , dec. 7, 2023 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today announced it has received 510(k) clearances from the u.s. federal drug administration (fda) for a novel blood collection device that obtains blood samples from a fingerstick that produce lab-quality results for some of the most commonly ordered blood tests.
BDX Ratings Summary
BDX Quant Ranking